Security of supply – why it matters to pharmaceuticals manufacturers and how predictive analytics can support it

27 August 2020
tablets_world_large

In these times especially, but far from exclusively, security of supply remains one of the biggest challenges for pharmaceuticals manufacturers, writes Justin Eames, senior manager, APM Solution Consulting, Aspen Technology, in an Expert View.

In this context, many of them have an intense focus on reducing supply chain disruption, increasing capacity of batch production and reducing batch losses. Reducing lifecycle maintenance costs and CAPEX remain high on the agenda, too. Notwithstanding compliance and safety, manufacturing equipment availability is therefore a top priority.

Scoping the challenge

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical